Bronte Capital Management Pty Ltd. Trims Stake in iShares Biotechnology ETF (NASDAQ:IBB)

Bronte Capital Management Pty Ltd. cut its holdings in iShares Biotechnology ETF (NASDAQ:IBB) by 3.1% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 264,586 shares of the financial services provider’s stock after selling 8,369 shares during the quarter. iShares Biotechnology ETF comprises 5.1% of Bronte Capital Management Pty Ltd.’s portfolio, making the stock its 6th largest position. Bronte Capital Management Pty Ltd.’s holdings in iShares Biotechnology ETF were worth $34,981,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the business. Darwin Wealth Management LLC acquired a new stake in shares of iShares Biotechnology ETF during the third quarter worth $29,000. HHM Wealth Advisors LLC raised its holdings in shares of iShares Biotechnology ETF by 200.0% during the fourth quarter. HHM Wealth Advisors LLC now owns 225 shares of the financial services provider’s stock worth $30,000 after acquiring an additional 150 shares during the period. Bradley & Co. Private Wealth Management LLC acquired a new stake in shares of iShares Biotechnology ETF during the fourth quarter worth $32,000. Newbridge Financial Services Group Inc. acquired a new stake in shares of iShares Biotechnology ETF during the fourth quarter worth $33,000. Finally, Hager Investment Management Services LLC acquired a new stake in shares of iShares Biotechnology ETF during the fourth quarter worth $34,000. 62.45% of the stock is owned by institutional investors.

iShares Biotechnology ETF Trading Down 1.4 %

Shares of IBB stock opened at $133.99 on Wednesday. iShares Biotechnology ETF has a 1 year low of $123.60 and a 1 year high of $150.57. The firm’s fifty day moving average price is $136.20 and its two-hundred day moving average price is $140.05. The firm has a market capitalization of $6.33 billion, a P/E ratio of 24.52 and a beta of 0.84.

iShares Biotechnology ETF Cuts Dividend

The firm also recently declared a dividend, which was paid on Friday, December 20th. Shareholders of record on Tuesday, December 17th were paid a $0.0624 dividend. The ex-dividend date was Tuesday, December 17th.

iShares Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.